Renaissance Technologies (RenTech)'s CRDF Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 101,253 shares of Cardiff Oncology, Inc. (CRDF) worth $164,030, representing 0.00% of the portfolio. First purchased in 2020-Q2, this medium-term investment has been held for 19 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in CRDF, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2022, adding 491,458 shares. Largest reduction occurred in Q1 2025, reducing 483,090 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Cardiff Oncology (CRDF) Holding Value Over Time
Track share changes against reported price movement
Quarterly Cardiff Oncology (CRDF) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +101,253 | New Buy | 101,253 | $1.62 |
| Q4 2025 | -101,800 | Sold Out | 0 | $0.00 |
| Q3 2025 | -27,890 | Reduce 21.51% | 101,800 | $2.06 |
| Q2 2025 | +129,690 | New Buy | 129,690 | $3.15 |
| Q1 2025 | -483,090 | Sold Out | 0 | $0.00 |
| Q4 2024 | -119,294 | Reduce 19.80% | 483,090 | $4.34 |
| Q3 2024 | +444,894 | Add 282.49% | 602,384 | $2.67 |
| Q2 2024 | +71,390 | Add 82.92% | 157,490 | $2.22 |
| Q1 2024 | -30,300 | Reduce 26.03% | 86,100 | $5.34 |
| Q4 2023 | -37,600 | Reduce 24.42% | 116,400 | $1.48 |
| Q3 2023 | -157,290 | Reduce 50.53% | 154,000 | $1.39 |
| Q2 2023 | -20,018 | Reduce 6.04% | 311,290 | $0.00 |
| Q1 2023 | -159,682 | Reduce 32.52% | 331,308 | $0.00 |
| Q4 2022 | +69,002 | Add 16.35% | 490,990 | $0.00 |
| Q3 2022 | -305,628 | Reduce 42.00% | 421,988 | $1.54 |
| Q2 2022 | +236,158 | Add 48.05% | 727,616 | $2.20 |
| Q1 2022 | +491,458 | New Buy | 491,458 | $2.48 |
| Q3 2020 | -268,800 | Sold Out | 0 | $0.00 |
| Q2 2020 | +268,800 | New Buy | 268,800 | $5.01 |
Renaissance Technologies (RenTech)'s Cardiff Oncology Investment FAQs
Renaissance Technologies (RenTech) first purchased Cardiff Oncology, Inc. (CRDF) in Q2 2020, acquiring 268,800 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Cardiff Oncology, Inc. (CRDF) for 19 quarters since Q2 2020.
Renaissance Technologies (RenTech)'s largest addition to Cardiff Oncology, Inc. (CRDF) was in Q1 2022, adding 491,458 shares worth $1.22 M.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 101,253 shares of Cardiff Oncology, Inc. (CRDF), valued at approximately $164,030.
As of the Q1 2026 filing, Cardiff Oncology, Inc. (CRDF) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Cardiff Oncology, Inc. (CRDF) was 727,616 shares, as reported at the end of Q2 2022.